MENU

ASCO 2018 Fox Chase Speaker Schedule

Session Time Presentation Time Session Type Session Title Presentation Title Room Speaker Name Abst ID Poster Board
2:45 PM - 4:00 PM 3:25 PM - 3:45 PM Education Session My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer: What Now? Novel Immunotherapy Combinations in the Initial Management of Non-Small Cell Lung Cancer Hall D1 Hossein Borghaei, DO, MS    
Session Time Presentation Time Session Type Session Title Presentation Title Room Speaker Name Abst ID Poster Board
8:00 AM - 11:30 AM   Poster Session Sarcoma A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI). Hall A Margaret von Mehren, MD 11533 278
1:15 PM - 4:45 PM   Poster Session Cancer Prevention, Hereditary Genetics, and Epidemiology Long-term (7-year) outcomes of universal mismatch repair screening (uMMR) of 1156 colorectal (CRC) and endometrial cancers (EC) in an academic setting. Hall A Michael J. Hall, MD, MS 1513 84
1:15 PM - 4:45 PM   Poster Session Cancer Prevention, Hereditary Genetics, and Epidemiology Feasibility of perioperative multi-gene panel testing (MGPT) in cancer patients eligible for hereditary genetic evaluation (GE): The PROTECT pilot. Hall A Michael J. Hall, MD, MS 1536 107
1:15 PM - 4:45 PM   Poster Session Health Services Research, Clinical Informatics, and Quality of Care Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC). Hall A Chethan Ramamurthy, BA, MD 6514 340
Session Time Presentation Time Session Type Session Title Presentation Title Room Speaker Name Abst ID Poster Board
8:00 AM - 11:00 AM 9:24 AM - 9:36 AM Oral Abstract Session Cancer Prevention, Hereditary Genetics, and Epidemiology Pathogenic somatic mutation (SM) of mismatch repair (MMR) genes and associations with microsatellite instability (MSI), tumor mutational burden (TMB) and SM in other DNA repair pathways in 24,223 tumor genomic profiles. S404 Joseph Nicholas Bodor, MD, PhD 1505  
8:00 AM - 11:30 AM   Poster Session Gastrointestinal (Noncolorectal) Cancer Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). Hall A Namrata Vijayvergia, MD 4104 293
8:00 AM - 11:30 AM   Poster Session Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer. Hall A Martin J. Edelman, MD TPS8588 190a
5:00 PM - 5:30 PM   Plenary Session Post-Plenary Discussion Session III: Kidney Cancer Panelist S100a David Chen, MD    
Session Time Presentation Time Session Type Session Title Presentation Title Room Speaker Name Abst ID Poster Board
7:30 AM - 9:15 AM 7:45 AM - 8:00 AM Highlights of the Day Session Highlights of the Day Session II Genitourinary (Nonprostate) Cancer Hall D1 Elizabeth R. Plimack, MD, MS    
8:00 AM - 11:30 AM   Poster Session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. Hall A Mark N. Stein, MD 2595 421
8:00 AM - 11:30 AM   Poster Session Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors. Hall A Stefan K. Barta, MD, MRCP, MS TPS7084 138b
8:00 AM - 11:30 AM   Poster Session Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma. Hall A Stefan K. Barta, MD, MRCP, MS 7568 205
1:15 PM - 4:45 PM   Poster Session Gynecologic Cancer Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514). Hall A Lainie P. Martin, MD 5580 307
1:15 PM - 4:45 PM   Poster Session Patient and Survivor Care Randomized trial of a text messaging intervention for symptom distress in BCa patients undergoing chemotherapy. Hall A Kuang-Yi Wen, PhD 10085 73
1:15 PM - 4:45 PM   Poster Session Tumor Biology Liquid biopsies (LB) across treatment of 29 metastatic colorectal cancer (mCRC) patients (pts) to reveal driver mutations and tumor evolution with anti-EGFR therapy: Experience in a GI oncology clinic at Fox Chase Cancer Center. Hall A Pooja Ghatalia, MD 12047 160
1:15 PM - 4:45 PM   Poster Session Tumor Biology Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq. Hall A Razelle Kurzrock, MD 12118 231
3:00 PM - 6:00 PM 3:12 PM - 3:24 PM Oral Abstract Session Lung Cancer—Non-Small Cell Metastatic Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. Hall B1 Hossein Borghaei, DO, MS 9001  
Session Time Presentation Time Session Type Session Title Presentation Title Room Speaker Name Abst ID Poster Board
8:00 AM - 11:00 AM 8:36 AM - 8:48 AM Oral Abstract Session Tumor Biology Circulating Biomarkers for Immunotherapy: Are They Ready for Your Clinic? S406 Hossein Borghaei, DO, MS    
Posted on Thursday, May 31, 2018
Fox Chase Cancer Center-Temple Health

About Fox Chase Conversations

Cancer Conversations is the Fox Chase Cancer Center blog for news and analysis from staff and friends of the Center, reflecting current news in the field of oncology.

View all posts

Tags

       

Connect with Fox Chase